L-alpha-glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat.
Level 5 - mechanism / opinion, no new human data
Preclinical animal and in vitro laboratory study
PubMed 1319912 · doi:10.1016/0014-2999(92)90392-h
What was done
Rats were treated with oral L-alpha-glycerylphosphorylcholine (alpha-GPC) 3 hours before testing to assess its ability to prevent scopolamine-induced learning impairment (scopolamine given 30 minutes prior to passive avoidance acquisition) and retrograde amnesia (scopolamine given immediately after training). The underlying mechanism was evaluated by measuring hippocampal acetylcholine synthesis and release via in vivo microdialysis and in vitro tissue slice assays, alongside intravenous [14C]alpha-GPC tracing to monitor conversion into [14C]acetylcholine.
What was found
Alpha-GPC dose-dependently prevented scopolamine-induced learning deficits and completely reversed retrograde amnesia, with maximal efficacy at 300 mg/kg. Microdialysis and slice assays showed a dose-dependent increase in hippocampal acetylcholine release that also peaked at 300 mg/kg. Tracing confirmed the direct formation of [14C]acetylcholine following [14C]alpha-GPC injection. Exact baseline values, percent changes, and variance metrics were not reported in the abstract.
Why it matters
This study provides early preclinical evidence that alpha-GPC acts as a bioavailable acetylcholine precursor capable of boosting central cholinergic transmission and rescuing drug-induced memory deficits in rodents.
Limits
Findings are limited to an acute rodent model of scopolamine-induced amnesia and cannot be directly extrapolated to human cognitive enhancement or chronic neurodegenerative disease. The abstract omits sample sizes (n), numerical effect sizes, and statistical test parameters.
Cited by
- supports Alpha-GPC supplementation increases levels of acetylcholine in the nervous system.